Kadmon is a fully integrated biopharmaceutical company that focuses on small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Its lead product candidates is KD025, a rho-associated coiled-coil kinase2 inhibitor, which is in Phase II clinical studies for the treatment of autoimmune, fibrotic, and neurodegenerative diseases. The company is headquartered in New York.
